Answers are grounded in this paper and cite their sources.
The antiplatelet drug ticlopidine was assessed as an agent for improving the patency of Brescia-Cimino arteriovenous fistulas as access for hemodialysis. In a double-blind randomized study over 1 month, two of six fistulas in the ticlopidine group and five of nine in the placebo group failed. A further one placebo and two ticlopidine patients still had functioning fistulas at the time of withdrawal for technical reasons from the trial. Ticlopidine appears, therefore, to enhance the efficacy of Brescia-Cimino fistulas, at least in the short term.
No takes yet. Share an insight, caveat, or question.
FISKERSTRAND et al. (1985) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: